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Table 1. Adjusted odds ratios for cardiovascular diseases associated
with an increase of one quintile in plasma sFas and CRP
Markers Odds ratio (95% CI)a P value
sFas 1.74 (1.21–2.89) 0.01
CRP 2.08 (1.11–3.24) 0.008
Abbreviations are: CRP, C-reactive protein; sFas, soluble Fas.
aOdds ratios are adjusted for the following additional risk factors: age, sex,
traditional risk factors for atherosclerosis (obesity, hypertension, hyperlipidemia,
smoking, and diabetes), serum albumin level, nutritional status (nPCR), and dial-
ysis adequacy (eKt/V).
mL/min) were enrolled. Clinical data included duration of
ESRD, traditional risk factors for CV disease (CVD),
normalized protein catabolic rate (nPCR) in g/kg/d, and
dialysis adequacy (eKt/V). Cardiovascular morbidity and
mortality criteria were myocardial infarction, angina pec-
toris, coronary artery revascularization, a positive stress
test, or cardiac imaging procedure. Hemodialysis and non-
HD ESRD patients had evidence of CVD compared with
control patients (P  0.02) with 11%, 6%, and 0% CV
mortality, respectively (P  0.01). Levels of sFas were
significantly higher in HD patients compared with non-
HD ESRD patients (P  0.02) and control patients (P 
0.01). After adjustment for traditional CV risk factors,
sFas and C-reactive protein (CRP) remained independent
markers of CVD (Table 1). The correlation between sFas
and CRP was R2  0.67 (P 0.005). These results suggest
that sFas may represent a novel and independent predictor
of CVD morbidity and mortality in ESRD patients. The
addition of sFas to the inflammatory factor CRP allows
better determination of CVD in ESRD patients.
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Dialysate calcium use in
hemodialysis patients
To the Editor: A recent Kidney International article [1]
demonstrates an impressive decrease in cardiac calcifica-
tion with the use of sevelamer as phosphate binder when
compared to calcium-based binders. However, there is a
striking omission in the data. Dialysate calcium is not
presented at all. Dialysate calcium doubtlessly has a strong
impact on most, if not all, of the study outcomes, including
serum calcium, phosphorus, and parathyroid hormone
(PTH) [2], and most probably, soft tissue calcification.
Dialysate calcium is an important variable that should
have been measured and presented to aid in the interpre-
tation of the study.
Another omission in the data is the mean PTH level.
The median of PTH levels that is given is an extremely
limited description of this important parameter in the
study. Why was the mean  SD not presented?
The omission of easy-to-obtain, pertinent variables, ob-
scures the clinical implications of this study.
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Renal disease medications
and evidence-biased medicine
To the Editor: In a recent article in Kidney International
[1] I read about a comparison between sevelamer and cal-
cium-containing substances. Although the paper seemed
quite scientific, I feel the need to state some objections.
The paper compares three different medications in he-
modialysis patients but considers two of them to be the
same: calcium carbonate and calcium acetate. The truth
is that these two calcium-containing substances are quite
different, both in their effectiveness and their side ef-
fects. The mixed data this paper presents from the pa-
tients in the United States and Europe who used calcium
acetate and calcium carbonate, respectively, is biased.
In many European countries calcium carbonate is the
only calcium-containing phosphate binder that exists. In
the United States, calcium acetate has been used for
several years, in many cases superseding calcium carbon-
ate. The trouble with this paper is that it does not say
how many patients used calcium carbonate and how
many used calcium acetate. It only says that half the
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patients used calcium-containing phosphate binders. A
more proper comparison would be among all three phos-
phate binders, not sevelamer and the other two together.
In order to decide which medication to prescribe at an
early stage or at any stage of renal disease, we need all
the data we can get. So let this decision be made on a
more evidence-based rather than evidence-biased basis.
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